N-isopropyl-N'-(4-methyl-2-pyrrolidin-1-ylquinolin-6-yl)thiourea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-isopropyl-N'-(4-methyl-2-pyrrolidin-1-ylquinolin-6-yl)thiourea
• 英文别名: 1-(4-methyl-2-pyrrolidin-1-ylquinolin-6-yl)-3-propan-2-ylthiourea
• 化学式: C₁₈H₂₄N₄S
• 分子量: 328.5
• InChiKey: LZLWVJTYIZYIIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  72.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE<br/>[FR] INHIBITEURS DE LA QUINOLÉINE DE RAD52 ET MÉTHODES D'UTILISATION
  申请人：UNIV DREXEL

  公开号：WO2021067604A1

  公开（公告）日：2021-04-08

  The present disclosure related to compounds of Formula I and Formula I and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating RAD51 activity and may be used in the treatment of disorders in which RAD51 activity is implication, such as a cancer.

  本公开涉及到Formula I和Formula I的化合物及其药用盐、药物组合物、使用方法和制备方法。本文披露的化合物可用于调节RAD51活性，并可用于治疗RAD51活性参与的疾病，如癌症。
• Parkin ligase activation methods and compositions
  申请人：An2H Discovery Limited

  公开号：US10155936B2

  公开（公告）日：2018-12-18

  The present invention is directed to methods and compositions for activating a Parkin ligase by administering to a subject in need thereof a therapeutically effective amount of a compound that disrupts at least one Parkin ligase zinc finger. The present invention is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase.

  本发明涉及通过向有需要的受试者施用治疗有效量的破坏至少一个Parkin连接酶锌指的化合物来激活Parkin连接酶的方法和组合物。本发明还涉及治疗和/或降低与激活Parkin连接酶有关的疾病或病症发病率的方法。
• PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS
  申请人：An2H Discovery Limited

  公开号：US20160160205A1

  公开（公告）日：2016-06-09

  The present invention is directed to methods and compositions for activating a Parkin ligase by administering to a subject in need thereof a therapeutically effective amount of a compound that disrupts at least one Parkin ligase zinc finger. The present invention is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase.
• QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE
  申请人：Drexel University

  公开号：US20220388980A1

  公开（公告）日：2022-12-08

  The present disclosure related to compounds of Formula I and Formula I and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating RAD52 activity and may be used in the treatment of disorders in which RAD52 activity is implication, such as a cancer.